Clinical Trial Update: Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the early bactericidal activity, safety and tolerability of oral GSK3036656 in combination with other antitubercular agents or standard…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• GSK3036656

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tuberculosis | Phase 2 | Status: COMPLETED